Bradley Jermy and Jonathan Coleman
The World Health Organisation reported in 2018 that approximately 300 million people suffer with major depression worldwide. Despite the impact of the disorder, treatments are not effective enough: only around 30% of participants remitted following treatment with citalopram, commonly regarded as the initial anti-depressant therapy. While research into areas such as genetics and inflammation have recently made great strides, it has been difficult to identify specific biomarkers for major depression.